Fresenius Medical Care AG & Co. KGaA (FMS) Cash Flow Statement

The ratio of operating cash flow to net income swung between roughly 1.1x and 12.4x across the ten quarters, which appears driven more by timing of working capital and non-cash charges than by underlying operating strength. A quarter with net income of only $66.9M alongside $831.7M of operating cash flow implies large non-cash add-backs and working capital releases that may not repeat. Investors should monitor whether this high conversion reflects durable cash economics or temporary balance sheet movements.

Free cash flow has oscillated materially, with two quarters in 2025 and early 2026 producing margins below 1%, which suggests working capital swings are dominating reported cash outcomes. The recent recovery to double-digit margins in the latter 2025 and 2026 quarters is encouraging but rests on only a few periods. Sustained evaluation requires confirming that margins above 11% persist through a full cycle.

The size of these swings relative to quarterly operating cash flow suggests that collections timing and payables management carry significant influence over reported results. Large outflows in early 2026 and 2025 may reflect receivables build-up tied to U.S. reimbursement timing, though the data alone cannot confirm this cause. Investors should monitor days sales outstanding for signs of structural collection friction.

Capex has generally run at a moderate level relative to the depreciation charge of roughly $370M to $460M per quarter, suggesting the asset base is being maintained at approximately replacement rates. The Q4 2025 step-up to $410.4M may reflect a discrete investment cycle rather than a new run-rate, which warrants confirmation. Sustained capex above depreciation would indicate growth investment rather than maintenance.

Cumulative buybacks and dividends over the period appear to absorb a substantial share of free cash flow, though the timing mismatch between high-FCF and low-FCF quarters complicates assessment of sustainability. Net acquisition outflows remain small relative to the cash base, suggesting limited reliance on M&A for growth. Investors should monitor whether repurchases continue if free cash flow margins revert toward the low end of their range.

Summing the disclosed quarters, operating cash flow materially outpaces reported net income, which suggests depreciation and amortization of roughly $370M to $460M per quarter are doing much of the work. Because D&A is recurring, a persistent gap of this kind would be expected in a capital-intensive model, but its size relative to net income warrants monitoring. Analysts should test whether the gap narrows as working capital normalizes.